Yinying Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yinying Chu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jian Chen
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
2 shared publications - Yi Fang
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
2 shared publications - Chao Xue
ENT Institute and Department of Otorhinolaryngology Eye & ENT Hospital, Fudan University Shanghai China
1 shared publication - Chunsheng Wei
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
1 shared publication - Dan Li
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital Fudan University Shanghai China
1 shared publication Guangfei Li
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
PD-L1 transmembrane domain substitution overcomes CAR-T exhaustion driven by tonic signaling
- 15 October 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
Open AccessPD-L1 transmembrane domain substitution overcomes CAR-T exhaustion driven by tonic signaling
- 4 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 351-359
Pathological Grading Determines the Clinical Efficacy of Outpatient KTP Laser Treatment for Vocal Fold Leukoplakia
Objective: Vocal fold leukoplakia is commonly managed with outpatient potassium titanyl phosphate (KTP) laser therapy; however, limited data exist on the impact of different pathological grades on long‐term efficacy. This study retrospectively analyzed the treatment outcomes, identified prognostic factors, and provided insights to improve disease characterization and clinical management. Study Design: Retrospective study (2017–2024). Methods: Ninety two patients with vocal fold leukoplakia treated in Fudan Eye and ENT hospital (FD‐EENT) were included. The mean follow‐up period after the last treatment was 20.53 ± 17.32 months. Disease control was assessed by lesion regression using ImageJ analysis. Acoustic outcomes were evaluated using the Voice Handicap Index‐30 (VHI‐30), GRBAS scale, and other acoustic parameters. Results: Patients underwent a mean of 1.6 treatment sessions. Following the last treatment, the lesion regression rates were 90.1% for no dysplasia, 81.75% for mild dysplasia, and 86.83% for moderate dysplasia, compared to 51.0% for severe dysplasia and 32.9% for carcinoma in situ (CIS). Patients with pathological grades of severe dysplasia and CIS showed significantly poorer treatment outcomes than those with milder dysplasia (*** p = 0.0001). Conclusion: Outpatient KTP laser effectively controls disease progression in vocal fold leukoplakia, with efficacy linked to the degree of dysplasia. KTP laser is an effective treatment for milder pathological dysplasia, but its efficacy diminishes in more severe stages. The treatment should be carefully considered for patients with severe dysplasia and CIS, with close follow‐up, and biopsy should be performed to monitor malignant transformation and prevent delayed treatment. Level of Evidence: 4.
- 4 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 351-359
Pathological Grading Determines the Clinical Efficacy of Outpatient KTP Laser Treatment for Vocal Fold Leukoplakia
Objective: Vocal fold leukoplakia is commonly managed with outpatient potassium titanyl phosphate (KTP) laser therapy; however, limited data exist on the impact of different pathological grades on long‐term efficacy. This study retrospectively analyzed the treatment outcomes, identified prognostic factors, and provided insights to improve disease characterization and clinical management. Study Design: Retrospective study (2017–2024). Methods: Ninety two patients with vocal fold leukoplakia treated in Fudan Eye and ENT hospital (FD‐EENT) were included. The mean follow‐up period after the last treatment was 20.53 ± 17.32 months. Disease control was assessed by lesion regression using ImageJ analysis. Acoustic outcomes were evaluated using the Voice Handicap Index‐30 (VHI‐30), GRBAS scale, and other acoustic parameters. Results: Patients underwent a mean of 1.6 treatment sessions. Following the last treatment, the lesion regression rates were 90.1% for no dysplasia, 81.75% for mild dysplasia, and 86.83% for moderate dysplasia, compared to 51.0% for severe dysplasia and 32.9% for carcinoma in situ (CIS). Patients with pathological grades of severe dysplasia and CIS showed significantly poorer treatment outcomes than those with milder dysplasia (*** p = 0.0001). Conclusion: Outpatient KTP laser effectively controls disease progression in vocal fold leukoplakia, with efficacy linked to the degree of dysplasia. KTP laser is an effective treatment for milder pathological dysplasia, but its efficacy diminishes in more severe stages. The treatment should be carefully considered for patients with severe dysplasia and CIS, with close follow‐up, and biopsy should be performed to monitor malignant transformation and prevent delayed treatment. Level of Evidence: 4.
- 18 January 2023
- Published by Springer Nature in Biotechnology Letters
- Vol. 45 (3) , 347-355
Establishment and characterization of immortalized human vocal fold fibroblast cell lines
Purpose Vocal fold scarring is abnormal scar tissue in the lamina propria layer of the vocal fold. To facilitate investigation of vocal fold scarring, we established and characterized immortalized human vocal fold fibroblast (iHVFF) cell lines. Methods Human vocal fold fibroblasts were immortalized by introducing Simian virus 40 large T antigen (SV40TAg) by transfection. Successfully transfected fibroblasts were sorted using flow cytometry. Immunofluorescence cytochemistry and western blot were applied to analyze the expression of fibronectin, vimentin, alpha-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP). Cell proliferation rate was measured by CCK-8 assay. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to analyze the mRNA expression level. Results The iHVFFs continued to proliferate for more than 30 generations and appeared spindle-shaped. The expression of Vimentin and α-SMA were detected in both iHVFFs and primary fibroblasts, and enhanced expression of FAP was observed in iHVFFs. Furthermore, iHVFFs exhibited an increased proliferative capability compared with the primary fibroblasts. RT-qPCR results suggested that collagen type III alpha 1 chain (COL3A1), interleukin-6, cyclooxygenase 2 (COX2), hyaluronan synthase 2 (HAS2), hepatocyte growth factor (HGF) in the iHVFFs significantly increased, whereas transforming growth factor-β1 (TGF-β1), elastin and matrix metallopeptidase-1 (MMP-1) expression significantly downregulated. No differences in mRNA expression of α-SMA, fibronectin and collagen type I alpha 2 chain (COL1A2) were noted between iHVFFs and primary fibroblasts. Conclusion iHVFFs can be used as a novel tool cell for future researches on the mechanisms of pathogenesis and treatment of vocal fold scarring.
- 18 January 2023
- Published by Springer Nature in Biotechnology Letters
- Vol. 45 (3) , 347-355
Establishment and characterization of immortalized human vocal fold fibroblast cell lines
Purpose Vocal fold scarring is abnormal scar tissue in the lamina propria layer of the vocal fold. To facilitate investigation of vocal fold scarring, we established and characterized immortalized human vocal fold fibroblast (iHVFF) cell lines. Methods Human vocal fold fibroblasts were immortalized by introducing Simian virus 40 large T antigen (SV40TAg) by transfection. Successfully transfected fibroblasts were sorted using flow cytometry. Immunofluorescence cytochemistry and western blot were applied to analyze the expression of fibronectin, vimentin, alpha-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP). Cell proliferation rate was measured by CCK-8 assay. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to analyze the mRNA expression level. Results The iHVFFs continued to proliferate for more than 30 generations and appeared spindle-shaped. The expression of Vimentin and α-SMA were detected in both iHVFFs and primary fibroblasts, and enhanced expression of FAP was observed in iHVFFs. Furthermore, iHVFFs exhibited an increased proliferative capability compared with the primary fibroblasts. RT-qPCR results suggested that collagen type III alpha 1 chain (COL3A1), interleukin-6, cyclooxygenase 2 (COX2), hyaluronan synthase 2 (HAS2), hepatocyte growth factor (HGF) in the iHVFFs significantly increased, whereas transforming growth factor-β1 (TGF-β1), elastin and matrix metallopeptidase-1 (MMP-1) expression significantly downregulated. No differences in mRNA expression of α-SMA, fibronectin and collagen type I alpha 2 chain (COL1A2) were noted between iHVFFs and primary fibroblasts. Conclusion iHVFFs can be used as a novel tool cell for future researches on the mechanisms of pathogenesis and treatment of vocal fold scarring.